Paper Details

  1. Home
  2. Paper Details

Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.

Author: ClarkeRobert, GoetzMatthew Philip, O'SullivanCiara Catherine, RobertsonJohn

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) have shown significant benefits for patients with hormone receptor-positive (HR+), ERBB2-negative (ERBB2-) advanced or metastatic breast cancer. Future research should focus on defining the role of each CDK4/6i in HR+ breast cancer and developing biomarker-directed integration of these agents.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: Combination therapy with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i: palbociclib, ribociclib, abemaciclib) and endocrine therapy (ET) has been a major advance for the treatment of hormone receptor-positive (HR+), ERBB2 (formerly HER2)-negative (ERBB2-) advanced or metastatic bre...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1001/jamaoncol.2023.2000

データ提供：米国国立医学図書館（NLM）

A New Weapon in the Arsenal Against Breast Cancer

Breast cancer is a challenging disease, and researchers are constantly searching for new and effective treatment options. This review explores the role of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) in the treatment of hormone receptor-positive (HR+), ERBB2-negative (ERBB2-) breast cancer. The researchers examine the current evidence and clinical applications of CDK4/6i, highlighting their potential to improve outcomes for patients with this type of breast cancer.

A Powerful Combination for Breast Cancer Treatment

The review highlights the significant advancements made in breast cancer treatment with the introduction of CDK4/6i. Combination therapy with CDK4/6i and endocrine therapy (ET) has demonstrated a significant reduction in disease progression, offering a new hope for patients with HR+, ERBB2- breast cancer. It's like discovering a new weapon in the arsenal against this formidable disease, offering a powerful combination for fighting breast cancer.

Navigating the Future of Breast Cancer Treatment

This review underscores the ongoing research and development in breast cancer treatment, emphasizing the importance of personalized medicine and biomarker-directed therapy. Researchers continue to investigate the best ways to use CDK4/6i and other targeted therapies, seeking to optimize treatment strategies and improve outcomes for patients. It's a journey of innovation and discovery, guided by the relentless pursuit of better treatments for breast cancer.

Dr.Camel's Conclusion

This review offers a glimpse into the evolving landscape of breast cancer treatment. The development of CDK4/6i represents a significant breakthrough, offering hope for patients with HR+, ERBB2- breast cancer. It's a testament to the power of research and collaboration in fighting this disease, and a reminder that the journey towards better treatment options is ongoing.

Date :
  1. Date Completed 2023-09-25
  2. Date Revised 2023-12-06
Further Info :

Pubmed ID

37382948

DOI: Digital Object Identifier

10.1001/jamaoncol.2023.2000

Related Literature

Article Analysis
・Effects of abemaciclib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.